CN113527151A - Action mechanism and application of anti-tumor small molecular compound - Google Patents
Action mechanism and application of anti-tumor small molecular compound Download PDFInfo
- Publication number
- CN113527151A CN113527151A CN202010314334.1A CN202010314334A CN113527151A CN 113527151 A CN113527151 A CN 113527151A CN 202010314334 A CN202010314334 A CN 202010314334A CN 113527151 A CN113527151 A CN 113527151A
- Authority
- CN
- China
- Prior art keywords
- tumor
- compound
- molecular
- small molecule
- cell carcinoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 25
- 230000000259 anti-tumor effect Effects 0.000 title claims abstract description 20
- 230000009471 action Effects 0.000 title description 5
- 230000007246 mechanism Effects 0.000 title description 5
- 239000003814 drug Substances 0.000 claims abstract description 18
- 229940079593 drug Drugs 0.000 claims abstract description 15
- 230000006907 apoptotic process Effects 0.000 claims abstract description 12
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 11
- 229940041181 antineoplastic drug Drugs 0.000 claims abstract description 10
- 201000002743 tongue squamous cell carcinoma Diseases 0.000 claims abstract description 10
- -1 small molecule compound Chemical class 0.000 claims description 27
- 230000035755 proliferation Effects 0.000 claims description 8
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 8
- 230000002401 inhibitory effect Effects 0.000 claims description 7
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 238000002347 injection Methods 0.000 claims description 6
- 239000007924 injection Substances 0.000 claims description 6
- 102000040945 Transcription factor Human genes 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 108091023040 Transcription factor Proteins 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- IUZGUIPYVGPQFT-UHFFFAOYSA-N N-[4-(naphthalen-2-ylmethyl)phenyl]ethenesulfonamide Chemical compound C(=C)S(=O)(=O)NC1=CC=C(C=C1)CC1=CC2=CC=CC=C2C=C1 IUZGUIPYVGPQFT-UHFFFAOYSA-N 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 238000013508 migration Methods 0.000 claims description 3
- 230000005012 migration Effects 0.000 claims description 3
- 229940124531 pharmaceutical excipient Drugs 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 239000007901 soft capsule Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 230000002222 downregulating effect Effects 0.000 claims description 2
- 230000004899 motility Effects 0.000 claims description 2
- 206010041865 Squamous cell carcinoma of the tongue Diseases 0.000 claims 2
- 239000003405 delayed action preparation Substances 0.000 claims 1
- 101000597035 Homo sapiens Transcriptional enhancer factor TEF-4 Proteins 0.000 abstract description 11
- 230000000694 effects Effects 0.000 abstract description 10
- 210000004881 tumor cell Anatomy 0.000 abstract description 10
- 206010027476 Metastases Diseases 0.000 abstract description 6
- 238000011161 development Methods 0.000 abstract description 6
- 230000009401 metastasis Effects 0.000 abstract description 6
- 206010064390 Tumour invasion Diseases 0.000 abstract description 3
- 230000002159 abnormal effect Effects 0.000 abstract description 3
- 230000009400 cancer invasion Effects 0.000 abstract description 3
- 230000009456 molecular mechanism Effects 0.000 abstract description 3
- 102000004169 proteins and genes Human genes 0.000 abstract description 2
- 108090000623 proteins and genes Proteins 0.000 abstract description 2
- 238000002512 chemotherapy Methods 0.000 abstract 1
- 238000002648 combination therapy Methods 0.000 abstract 1
- 238000002651 drug therapy Methods 0.000 abstract 1
- 229940124530 sulfonamide Drugs 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 19
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 15
- 102100035146 Transcriptional enhancer factor TEF-4 Human genes 0.000 description 9
- 239000002904 solvent Substances 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- JOXWSDNHLSQKCC-UHFFFAOYSA-N ethenesulfonamide Chemical compound NS(=O)(=O)C=C JOXWSDNHLSQKCC-UHFFFAOYSA-N 0.000 description 4
- 230000009545 invasion Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000001640 apoptogenic effect Effects 0.000 description 3
- 230000004709 cell invasion Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000004393 prognosis Methods 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 208000012147 squamous cell carcinoma of the oral tongue Diseases 0.000 description 3
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 201000002740 oral squamous cell carcinoma Diseases 0.000 description 2
- JUJBNYBVVQSIOU-UHFFFAOYSA-M sodium;4-[2-(4-iodophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].C1=CC([N+](=O)[O-])=CC=C1N1[N+](C=2C=CC(I)=CC=2)=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=N1 JUJBNYBVVQSIOU-UHFFFAOYSA-M 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 102000000412 Annexin Human genes 0.000 description 1
- 108050008874 Annexin Proteins 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 238000007808 Cell invasion assay Methods 0.000 description 1
- 208000007433 Lymphatic Metastasis Diseases 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000012137 double-staining Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000009650 gentamicin protection assay Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000011242 molecular targeted therapy Methods 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- UFWIBTONFRDIAS-UHFFFAOYSA-N naphthalene-acid Natural products C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000030968 tissue homeostasis Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/11—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic unsaturated carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention provides a function and a possible molecular mechanism of an anti-tumor small molecular compound, wherein the compound is N- (4- (naphthalene-2-ylmethyl) phenyl) ethylene sulfonamide, and the molecular formula is C18H25N3O4The molecular structural formula is:
the possible molecular mechanism of the small molecular compound is that the protein expression of an important transcription factor TEAD2 molecule in tongue squamous cell carcinoma is obviously reduced, so that the abnormal increase of tumor cells is inhibited, the apoptosis of the tumor cells is promoted, and the tumor invasion and metastasis capacity is inhibited. By molecular targeted therapyThe treatment effect is improved, and the toxic and side effects brought by broad-spectrum chemotherapy medicaments are reduced. The compound has a simple structure, is easy to synthesize, lays a good foundation for the development of new antitumor drugs, particularly innovative targeted drugs for tongue squamous cell carcinoma, and provides a wider application prospect for later-stage single-drug therapy and combined therapy.
Description
Technical Field
The invention belongs to the technical field of medicines, and particularly relates to an action mechanism and application of an anti-tumor small molecular compound.
Background
Malignant tumors are one of the diseases that seriously endanger human health. Tongue Squamous Cell Carcinoma (OTSCC) is one of the most common malignant tumors of Oral cavity, jaw and face, and seriously threatens the life and health of patients due to its biological characteristics such as high probability of lymph node metastasis and strong invasiveness. The traditional treatment method has certain influence on the long-term prognosis and the quality of life of patients, and the 5-year survival rate is low. In addition, the various molecular mechanisms involved in the disease have not been fully elucidated. Therefore, identification of effective biomarkers is crucial to improve the diagnosis, treatment and prognostic evaluation prevention of OTSCC.
The TEADs family has been shown to be an important class of transcription factors, which are widely involved in the development of malignant tumors. Since the first discovery, TEADs were found to be evolutionarily conserved and play an important role in development, tissue homeostasis, and tumorigenesis by regulating cell growth, proliferation, differentiation, and survival. Previous studies showed that the TEAD2 molecule was more highly expressed in OTSCC samples than in paracancerous samples. Meanwhile, the abnormally expressed TEAD2 is involved in the abnormal proliferation, invasion and metastasis and other biological phenotypes of tongue squamous cell carcinoma. The highly expressed TEAD2 may also affect the prognosis of tongue squamous carcinoma to some extent. Therefore, the molecule is expected to become a new target for treating tongue squamous cell carcinoma.
Throughout the research of antitumor drugs, molecular targeted therapy has gradually replaced broad-spectrum chemotherapeutic drugs and gradually moved to the market. The research and development of novel antitumor drugs according to the strategy have great significance for the development of malignant tumor treatment technology.
Disclosure of Invention
The invention aims to provide an action mechanism and application of an anti-tumor small molecule compound, wherein the compound can show good anti-tumor activity by down-regulating the expression of a transcription factor TEAD 2.
In order to achieve the purpose, the invention adopts the technical scheme that:
an anti-tumor small molecular compound, which is characterized in that the compound is N- (4- (naphthalene)-2-ylmethyl) phenyl) ethenesulfonamide having the formula C19H18NOS, molecular structural formula:
the anti-tumor small molecular compound is applied to preparing anti-tumor drugs.
The tumor is tongue squamous cell carcinoma.
The application is characterized in that the small molecule compound can specifically down regulate the expression level of the transcription factor TEAD 2.
The application is characterized in that the small molecular compound is a drug capable of inhibiting proliferation of tongue squamous carcinoma cells.
The application is characterized in that the small molecular compound is a drug capable of promoting tongue squamous cell carcinoma apoptosis.
The application is characterized in that the small molecular compound can inhibit the migration and the movement ability of tongue squamous carcinoma cells.
The anti-tumor drug is a drug prepared from N- (4- (naphthalene-2-ylmethyl) phenyl) ethenesulfonamide and one or more pharmaceutically acceptable auxiliary materials and/or pharmaceutical excipients.
The dosage forms of the antitumor drug comprise liquid preparations, tablets, medicinal granules, soft capsules, sustained-release agents, dropping pills and injections, and the administration forms comprise oral administration and injection administration.
Compared with the prior art, the invention has the beneficial effects that:
the invention provides an anti-tumor small molecule compound, N- (4- (naphthalene-2-ylmethyl) phenyl) vinylsulfonamide, which has good targeting property and good anti-tumor activity, can be used for preparing anti-tumor medicaments, and has good clinical application prospect.
Furthermore, experimental verification proves that the small molecule compound provided by the invention can reduce the expression level of the transcription factor TEAD2 protein, and has good targeting property. The TEAD2 is used as a target point to prevent and treat the oral squamous cell carcinoma, and a new strategy is provided for treating the oral squamous cell carcinoma.
Furthermore, experimental verification proves that the anti-tumor small molecule compound N- (4- (naphthalene-2-ylmethyl) phenyl) vinylsulfonamide provided by the invention has good anti-tumor activity, and has the effects of inhibiting abnormal proliferation, promoting apoptosis and inhibiting migration and metastasis of different squamous cancer cell lines, particularly oral tongue squamous cancer cell lines. Lays a good foundation and optimistic application prospect for the development of new anti-tumor drugs and brings good news for the majority of tumor patients.
Furthermore, the antitumor small molecule compound provided by the invention can be prepared into a medicament with any one or more pharmaceutically acceptable auxiliary materials and/or pharmaceutical excipients, the preparation can be any pharmaceutically acceptable dosage form, including but not limited to liquid preparations, tablets, granules, soft capsules, sustained release agents, dropping pills or injections, and the administration forms mainly include oral administration and injection administration.
Drawings
FIG. 1 is a molecular structural formula of an anti-tumor small molecule compound.
FIG. 2 shows the expression of TEAD2 protein level in Cal-27 cells at different drug concentrations.
FIG. 3 shows the effect of small molecule compounds on the proliferation ability of tumor cells under different drug concentrations detected by the WST-1 method.
FIG. 4 is a graph showing the effect of a small molecule compound on the apoptosis ability of tumor cells detected by a flow cytometry ANNEXIN-V/PI method, wherein the upper group is a schematic apoptosis flow chart; the lower panel is a statistical result chart.
Fig. 5 is the results of invasion assay to evaluate the effect of small molecule compounds on tumor invasion and motility. Wherein the upper group is a schematic representation of cell invasion; the lower panel is a statistical result chart.
Detailed Description
The present invention is described in further detail below.
The anti-tumor small molecular compound provided by the invention is N- (4- (naphthalene-2-ylmethyl) phenyl) vinylsulfonamide, and the molecule thereofFormula is C19H18NOS, molecular structural formula is shown in FIG. 1.
The anti-tumor effect of the anti-tumor small molecule compound provided by the invention is described in detail by specific experiments and the accompanying drawings.
1. Small molecule compounds down-regulate expression of TEAD2
Western blot is used for detecting the expression condition of the small molecular compound to TEAD2 molecular level in a tongue squamous carcinoma cell line Cal-27. As shown in fig. 2, the experimental results indicate that small molecule compounds can significantly down-regulate the protein expression level of TEAD2 in Cal-27 cells, and that this down-regulation is concentration-dependent. I.e., the higher the concentration of small molecule compound, the more pronounced the downregulation of TEAD 2. The test result indicates that the small molecular compound can remarkably reduce the expression of TEAD2, and is expected to become a candidate target compound of the target.
2. Small molecule compound for inhibiting proliferation capacity of Cal-27 cell
In order to detect whether the small molecular compound has influence on the proliferation activity of CAL-27 cells, the WST-1 kit is used for detection. As shown in FIG. 3, compared with the control group, the cell proliferation ability of the drug-intervention group was significantly inhibited, the cell survival rate was gradually decreased, and the concentration gradient dependence was exhibited (P < 0.05). Under the same culture time and treatment conditions, after 48 hours, the cell survival rate of the control group is still nearly 100%, while the cell survival rate of the highest concentration drug group is less than 5%, and the tumor inhibition effect is very obvious.
3. Small molecule compound for promoting CAL-27 cell apoptosis
A flow cytometer Annexin V-PI double staining test is applied to compare whether the small molecular compound can induce the tumor cells to generate apoptosis, as shown in figure 4. Considering that the solvent DMSO of small molecule compound also has some influence on the apoptosis of tumor cells, we introduced blank control group and solvent control group (DMSO) in this experiment. The results show that compared with the blank control group, the proportion of the apoptotic cells of the solvent control group is not obviously increased, no statistical difference exists between the two groups, while the proportion of the apoptotic cells of the drug intervention group is obviously increased, and the statistical difference exists between the apoptotic cells of the drug intervention group and the control group (P is less than 0.05). The compound is suggested to be capable of effectively inducing CAL-27 cells to generate apoptosis and eliminating the influence of a solvent DMSO on the apoptosis.
4. Micromolecular compound for inhibiting tongue squamous carcinoma invasion and metastasis
Tongue squamous carcinoma cells are easy to invade and transfer, can accelerate the progress of diseases, and seriously affect the prognosis. We evaluated the effect of this small molecule compound on the ability of cell invasion by the transwell cell invasion assay. Considering that the solvent DMSO of small molecule compound also has an effect on tumor invasion, blank control and solvent control (DMSO) were also introduced in this experiment. As shown in fig. 5, we found that the cell invasion ability of the solvent control group was not inhibited and was not significantly different from that of the blank control group, compared with that of the blank control group. After the drug is dried, the number of cells passing through the chamber is obviously reduced in each visual field, and the invasion and metastasis capacity of the cells is obviously inhibited. At a drug concentration of 10. mu.M, the invasive potential of tumor cells decreased by about 50%.
The data show that the possible action mechanism of the small molecular compound is that the expression level of a transcription factor TEAD2 which is important in the occurrence and development process of tongue squamous cell carcinoma is obviously reduced, so that the proliferation of tumor cells is further inhibited, the apoptosis of the tumor cells is promoted, and the invasion and metastasis capacity of the tumor cells is inhibited, thereby effectively controlling the tumor progression.
Claims (9)
1. An anti-tumor small molecular compound is characterized in that the compound is N- (4- (naphthalene-2-ylmethyl) phenyl) ethenesulfonamide, and the molecular formula is C19H18NOS, molecular structural formula:
2. the use of the anti-tumor small molecule compound of claim 1 in the preparation of anti-tumor drugs.
3. The tumor of claim 2, which is squamous cell carcinoma of the tongue.
4. The use of claim 2, wherein said small molecule compound is capable of specifically down-regulating the expression level of the transcription factor TEAD 2.
5. The use according to claim 2, wherein the small molecule compound is a drug capable of inhibiting proliferation of a tongue squamous carcinoma cell.
6. The use of claim 2, wherein the small molecule compound is a drug that promotes apoptosis in squamous cell carcinoma of the tongue.
7. The use according to claim 2, wherein the small molecule compound is capable of inhibiting migration and motility of squamous cell carcinoma cells.
8. The use according to any one of claims 4 to 7, wherein the antineoplastic drug is a drug prepared from N- (4- (naphthalene-2-ylmethyl) phenyl) ethenesulfonamide and one or more pharmaceutically acceptable excipients and/or pharmaceutical excipients.
9. The use of claim 8, wherein the dosage forms of the antitumor drugs include liquid preparations, tablets, granules, soft capsules, sustained-release preparations, dripping pills and injections, and the administration forms include oral administration and injection administration.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010314334.1A CN113527151A (en) | 2020-04-17 | 2020-04-17 | Action mechanism and application of anti-tumor small molecular compound |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010314334.1A CN113527151A (en) | 2020-04-17 | 2020-04-17 | Action mechanism and application of anti-tumor small molecular compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113527151A true CN113527151A (en) | 2021-10-22 |
Family
ID=78123703
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010314334.1A Pending CN113527151A (en) | 2020-04-17 | 2020-04-17 | Action mechanism and application of anti-tumor small molecular compound |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113527151A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112010789A (en) * | 2019-05-31 | 2020-12-01 | 中国科学院上海药物研究所 | Vinyl sulfonamide or vinyl amide compounds, and preparation method and application thereof |
-
2020
- 2020-04-17 CN CN202010314334.1A patent/CN113527151A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112010789A (en) * | 2019-05-31 | 2020-12-01 | 中国科学院上海药物研究所 | Vinyl sulfonamide or vinyl amide compounds, and preparation method and application thereof |
Non-Patent Citations (2)
| Title |
|---|
| WENCHAO LU ET AL.: "Discovery and biological evaluation of vinylsulfonamide derivatives as highly potent, covalent TEAD autopalmitoylation inhibitors", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 184, 9 October 2019 (2019-10-09), pages 111767, XP085911111, DOI: 10.1016/j.ejmech.2019.111767 * |
| ZHONGWU LI ET AL.: "The Hippo transducer TAZ promotes epithelial to mesenchymal transition and cancer stem cell maintenance in oral cancer", MOLECULAR ONCOLOGY, vol. 9, 9 February 2015 (2015-02-09), pages 1091 - 1105, XP029172008, DOI: 10.1016/j.molonc.2015.01.007 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112138142B (en) | Application of microcystin-RR in preparation of medicine for preventing or treating renal fibrosis diseases | |
| WO2019091183A1 (en) | Applications of yd1701 in preparation of drugs for treating aldh1a3 high-expression tumors | |
| WO2020087938A1 (en) | Use of spleen tyrosine kinase as therapeutic target of intrahepatic cholangiocarcinoma | |
| CN113521245B (en) | Pharmaceutical application of reduced glutathione in prevention of pulmonary nodule from increasing malignant transformation | |
| CN108295085B (en) | Application of protodioscin in preparation of drug-resistant osteosarcoma drug | |
| CN113527151A (en) | Action mechanism and application of anti-tumor small molecular compound | |
| CN112618527B (en) | Application of small molecule in preparation of mutant type uveal melanoma medicine | |
| CN108379583B (en) | Target for drug therapy of tumor metastasis and application thereof | |
| CN111297871A (en) | Application of radix stemonae alkaloid analogue | |
| CN107243079B (en) | A pharmaceutical composition containing rhein and its application in preparing antitumor drugs | |
| CN113440519A (en) | Application of mycophenolic acid and derivatives thereof in preparation of drugs for targeted therapy of cancers | |
| US10688086B2 (en) | Method for treating cancer with dihydropyridine calcium antagonist | |
| CN111184726A (en) | β -lactam compound application | |
| CN114288410B (en) | Application of SRC inhibitor and FAK inhibitor in preparation of medicines for inhibiting lung cancer metastasis | |
| KR102658209B1 (en) | Pharmaceutical composition for preventing or treating bladder cancer comprising a CDK inhibitor and an ID2 activator | |
| CN110627733A (en) | Action mechanism and application of anti-tumor small molecular compound | |
| CN109602730B (en) | Application of resveratrol and dihydroartemisinin in treating liver cancer and breast cancer and product thereof | |
| CN115212203A (en) | Application of gomisin G in preparation of anti-pancreatic cancer drug | |
| US20050232915A1 (en) | Matrix metalloproteinase inhibitors in combination with hypothermia and/or radiotherapy for the treatment of cancer | |
| Ruan et al. | Growth Arrest Specific Gene 6 Promotes Proliferation and Invasion of Laryngeal Cancer Cells Through the Vascular Endothelial Growth Factor (VEGF)/Protein Kinase B (AKT) Pathway | |
| CN114028380A (en) | Application of naringenin in preparing medicine for treating intestinal flora disorder caused by ovarian cancer | |
| CN113577053A (en) | Application of luteolin in preparation of medicine for targeted inhibition of ovarian cancer stem cells | |
| CN115505022A (en) | Alkaloid glycoside and application thereof | |
| CN116173032A (en) | Application of stevioside derivative in preparation of medicine for improving sensitivity of prostate cancer chemotherapy | |
| CN118021804A (en) | Application of clotrimazole in preparing medicine for treating ovarian cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20230807 Address after: No. 18-D12168, Jianshe Road, Kaixuan Street, Liangxiang, Fangshan District, Beijing 102488 Applicant after: Beijing Huifang Medical Technology Co.,Ltd. Address before: 210049 18 Xianlin Road, Ma Qun street, Qixia District, Nanjing, Jiangsu. Applicant before: Nanjing Ningyu Medical Equipment Co.,Ltd. |